ReviewMaterials today. Bio2026
Metal-based nanomaterials achieve tumor treatment strategies by overcoming the blood-brain barrier of glioma and responding to the tumor microenvironment.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy.International journal of pharmaceutics: X · 2026Review
- Bufalin-Loaded Multifunctional Nanodrugs for Cancer Therapy: Mechanisms, Delivery Strategies, and Translational Perspectives.Biomolecules · 2026Review
- Construction of EGFR-Targeted Triptolide Liposomes Using Uniform Design Optimization and Therapeutic Evaluation in Gliomas.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cross-linked (R)-(+)-lipoic acid nanoparticles loaded with silibinin induce apoptosis and autophagy in glioblastoma cells.American journal of translational research · 2026Article
- Advances in the Rational Design, Mechanisms, and Applications of Lanthanide Nanoparticles for the Regulation of Reactive Oxygen Species.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) continues to be the most lethal form of primary brain tumor. Therapeutic efficacy is significantly hindered by the presence of the blood-brain barrier (BBB) and the complex tumor microenvironment (TME), both of which contribute to the development of drug resistance. Metal-based nanomaterials have demonstrated considerable promise as therapeutic agents capable of overcoming these critical barriers. This article provides a systematic review of recent advances in the development of TME-responsive metal-based nanomaterials for GBM diagnosis and treatment. To accomplish controlled drug release, enhance imaging performance, and enable synergistic therapeutic approaches-including chemodynamic therapy (CDT), piezodynamic therapy (PZDT), gene therapy, and immunotherapy (IMT), and so on-the role of artificial intelligence (AI) in supporting treatment strategies is also examined. The discussion highlights how these nanomaterials are engineered to exploit distinctive features of the TME. Furthermore, targeted functionalization strategies designed to improve penetration across the BBB are analyzed. Finally, a critical evaluation of translational challenges and potential clinical applications is presented, offering insights that could advance a new paradigm in GBM therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.